HomeREGULATORY
REGULATORY

CSIMC Recommends NHI Price Listing for 15 APIs/20 Products
(Sep.7.2011)

At a general meeting on September 7, the Central Social Insurance Medical Council (CSIMC; Chuikyo) recommended NHI price listing for 15 APIs (active pharmaceutical ingredients)/20 products, including AstraZeneca’s proton pump inhibitor (PPI) Nexium capsule 10 mg and 20 mg (esomeprazole magnesium) and Astellas Pharma’s treatment for overactive bladder Betanis Tablet 25 mg and 50 mg (mirabegron). The adrenal hormone preparation EpiPen Injection 0.15 mg and 0.3 mg (adrenaline) will be added to the NHI price list on September 22. Other products will be included in the NHI price list on September 12.
> Read full story

Commentary

Open Innovation Bandwagon Gathers Pace for Efficient Drug Discovery

Lexicon

Conditional, Time-Limited Approval:
条件・期限付き承認

The Column

Eliminating Bias from the Interview Process

Archives

IMI, WADA Sign MOU to Prevent Use of Experimental Drugs for Doping(Jan.30)
Drug Wholesalers Should Stress Annual Price Cuts “Infeasible”: Ex-Minister(Jan.30)
MHLW Warns of Severe Febrile Neutropenia for Cabazitaxel(Jan.30)
Drug Discovery Support Project for Academia to Receive 3-Fold Budget Increase in FY2015(Jan.30)
Chugai to Set Up Global Organization to Bolster Early Clinical Development Functions(Jan.30)

Most Read

1.
Japan-Version C...
2.
Editor’s Pick: ...
3.
Chuikyo Members...
4.
Council OKs App...
5.
Chuikyo’s HTA P...

News Calendar